1. Home
  2. HKIT vs NEUP Comparison

HKIT vs NEUP Comparison

Compare HKIT & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HKIT

Hitek Global Inc.

HOLD

Current Price

$1.06

Market Cap

25.2M

Sector

Technology

ML Signal

HOLD

NEUP

Neuphoria Therapeutics Inc.

HOLD

Current Price

$4.59

Market Cap

23.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
HKIT
NEUP
Founded
1996
1996
Country
China
United States
Employees
N/A
8
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
25.2M
23.0M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
HKIT
NEUP
Price
$1.06
$4.59
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$21.00
AVG Volume (30 Days)
71.4K
57.0K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.53
$3.65
52 Week High
$4.21
$21.31

Technical Indicators

Market Signals
Indicator
HKIT
NEUP
Relative Strength Index (RSI) 32.27 60.87
Support Level $0.53 $3.92
Resistance Level $1.44 $5.06
Average True Range (ATR) 0.20 0.25
MACD -0.04 0.02
Stochastic Oscillator 36.35 70.35

Price Performance

Historical Comparison
HKIT
NEUP

About HKIT Hitek Global Inc.

Hitek Global Inc is a provider of information technology consulting and solutions services. The company has two lines of businesses such as services to small and medium businesses, which consist of Anti-Counterfeiting Tax Control System tax devices, including Golden Tax Disk and printers, ACTCS services, and IT services; and services to large businesses, which include hardware sales and software sales. It generates revenues from hardware sales, software sales, IT services, and tax devices and services.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: